Fully human antibodies, entirely encoded by human genes, offer a significant advantage in antibody drug development. They trigger minimal immune response (immunogenicity) in patients, leading to improved safety and tolerance compared to traditional antibody therapies. This approach also focuses on identifying high-affinity and highly specific antibodies, ensuring they effectively target the desired molecules. Previously, researchers relied on humanized mice, genetically modified to produce human antibodies, for this purpose.
However, with the innovative combination of Biointron’s AbDrop™ and Cyagen’s HUGO-Ab™ mice enables more efficient fully human antibody discovery. Our High-throughput Fully Human Antibody Discovery Platform eliminates the need for complex modifications and simplifies the development process, reducing costs and accelerating the discovery of safer and more effective antibody drugs.
✅ From Target to Fully Human Antibody in Just 3 Months!
🎯 Enhanced Accuracy & Diversity
💯 Clear IP & No Royalty Fee
⭐ Significantly Reduced Development Costs
If you have questions, don’t hesitate to contact us at 📩 info@biointron.com | 📞 +1(732)790-8340
Learn more here: https://www.biointron.com/antibody-discovery/high-throughput-fully-human-antibody-discovery-platform.html